KYTX - Kyverna Therapeutics, Inc.
2.02
0.010 0.495%
Share volume: 169,518
Last Updated: 05-07-2025
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
-0.02%
PREVIOUS CLOSE
CHG
CHG%
$2.01
0.01
0.01%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | |
|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | |
| Report Date | 05-14-2024 | 08-12-2024 | 11-13-2024 | 03-27-2025 | |
| Total revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 0.000 | 0.000 | |
| nan% | nan% | nan% | |||
| Operating expenses | 29.358 M | 33.435 M | 38.770 M | 41.041 M | |
| Selling general and admin | 6.882 M | 6.114 M | 9.577 M | 7.558 M | |
| Research and development | 22.476 M | 27.321 M | 29.193 M | 33.483 M | |
| Total expenses | 29.358 M | 33.435 M | 38.770 M | 41.041 M | |
| 13.89% | 15.96% | 5.86% | |||
| Operating income | -29.358 M | -33.435 M | -38.770 M | -41.041 M | |
| Ebit | -29.384 M | -33.458 M | -38.815 M | -41.037 M | |
| Pretax income | -26.693 M | -28.803 M | -34.492 M | -37.489 M | |
| 7.90% | 19.75% | 8.69% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -26.693 M | -28.803 M | -34.492 M | -37.489 M | |
| -7.90% | -19.75% | -8.69% |
